Furthermore, the change of ER‐ or PR‐negative disease to positive is also clinically unclear, since HR‐negative disease such as Triple‐negative and HER2neu cancers have other tumor biology and are not candidates for endocrine therapy. Here, ESR1 is linked to neoplasm.